DK0939590T3 - Nukleinsyre til anvendelse i genterapi, der involverer ekspression af tarmcellegener - Google Patents

Nukleinsyre til anvendelse i genterapi, der involverer ekspression af tarmcellegener

Info

Publication number
DK0939590T3
DK0939590T3 DK97942543T DK97942543T DK0939590T3 DK 0939590 T3 DK0939590 T3 DK 0939590T3 DK 97942543 T DK97942543 T DK 97942543T DK 97942543 T DK97942543 T DK 97942543T DK 0939590 T3 DK0939590 T3 DK 0939590T3
Authority
DK
Denmark
Prior art keywords
protein
administration
nucleic acid
gene therapy
cell genes
Prior art date
Application number
DK97942543T
Other languages
Danish (da)
English (en)
Inventor
Michael German
Ira D Goldfine
Stephen S Rothman
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK0939590T3 publication Critical patent/DK0939590T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK97942543T 1996-09-19 1997-09-18 Nukleinsyre til anvendelse i genterapi, der involverer ekspression af tarmcellegener DK0939590T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/717,084 US6225290B1 (en) 1996-09-19 1996-09-19 Systemic gene therapy by intestinal cell transformation

Publications (1)

Publication Number Publication Date
DK0939590T3 true DK0939590T3 (da) 2006-07-24

Family

ID=24880656

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97942543T DK0939590T3 (da) 1996-09-19 1997-09-18 Nukleinsyre til anvendelse i genterapi, der involverer ekspression af tarmcellegener

Country Status (10)

Country Link
US (4) US6225290B1 (https=)
EP (1) EP0939590B1 (https=)
JP (1) JP2001502303A (https=)
AT (1) ATE320186T1 (https=)
AU (1) AU729457B2 (https=)
CA (1) CA2264744A1 (https=)
DE (1) DE69735496T2 (https=)
DK (1) DK0939590T3 (https=)
ES (1) ES2256896T3 (https=)
WO (1) WO1998011779A1 (https=)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6225290B1 (en) * 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
US20030129750A1 (en) * 1998-02-05 2003-07-10 Yitzhack Schwartz Homing of donor cells to a target zone in tissue using active therapeutics or substances
US7749215B1 (en) * 1998-02-05 2010-07-06 Biosense, Inc. Intracardiac cell delivery and cell transplantation
US20030113303A1 (en) * 1998-02-05 2003-06-19 Yitzhack Schwartz Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances
AU3072799A (en) 1998-03-19 1999-10-11 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
WO1999049029A1 (en) * 1998-03-20 1999-09-30 Benitec Australia Ltd Control of gene expression
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
BR9909918A (pt) * 1998-05-06 2000-12-26 Upjohn Co Método para a liberação de um hormÈnio de crescimento ou citocina de proteìna, peptìdeo ou polipeptìdeo fisiologicamente ativos a um vertebrado não-humano
JPH11335269A (ja) * 1998-05-19 1999-12-07 Hisamitsu Pharmaceut Co Inc 遺伝子関連医薬の経口投与固形製剤
EP1889914A1 (en) * 1999-02-19 2008-02-20 Engene, Inc. Compositions for gene therapy of diabetes
US6503887B1 (en) * 1999-02-19 2003-01-07 Matthew During Peroral gene therapy of diabetes and obesity
EP2357192A1 (en) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Human endokine alpha and methods of use
DK1159415T3 (da) * 1999-03-04 2010-05-03 Revivicor Inc Genetisk modifikation af somatiske celler og anvendelse deraf
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US6953658B2 (en) 2000-03-09 2005-10-11 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancer
DK1274464T3 (da) 2000-03-13 2012-01-23 Engene Inc Sammensætninger og fremgangsmåder til regulering af proteinekspression i tarm
PT1309726E (pt) * 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
EP2206720A1 (en) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
GB0010630D0 (en) * 2000-05-04 2000-06-21 Univ Wales Medicine Sequence
CA2413160A1 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
WO2002000939A2 (en) 2000-06-28 2002-01-03 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
US20040259247A1 (en) 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
US20020151068A1 (en) * 2001-01-03 2002-10-17 Board Of Regents, The University Of Texas System Compositions and methods for the diagnosis and treatment of organophosphate toxicity
JP2005503116A (ja) 2001-02-09 2005-02-03 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド ヒトｇタンパク質ケモカインレセプター（ｃｃｒ５）ｈｄｇｎｒ１０
AU2002338345A1 (en) * 2001-04-04 2002-10-21 Digital Gene Technologies, Inc. Genes expressed in intestinal epithelium and peyer's patch m cells
CA2444632A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
AU2002311777A1 (en) * 2001-04-17 2002-10-28 Genetix Pharmaceuticals, Inc. Method of treating arthritis using lentiviral vectors in gene therapy
EP1404713A4 (en) * 2001-05-24 2004-09-22 Human Dna Technology Inc NEW KERATINOCYTE GROWTH FACTOR 2 ANALOG IN HAIR FOLLICULES
AU2002365188A1 (en) * 2001-11-07 2003-07-30 Musc Foundation For Research Development Nucleic acid delivery and expression
US20030135195A1 (en) * 2002-01-16 2003-07-17 Oscar Jimenez Highly lubricious hydrophilic coating utilizing dendrimers
DE60336754D1 (de) 2002-02-14 2011-05-26 Univ R Enzymbehandlung von nahrungsmitteln für zöliakie-sprue
WO2003104439A2 (en) * 2002-03-12 2003-12-18 Surface Logix, Inc. Assay device that analyzes the absorption, metabolism, permeability and/or toxicity of a candidate compound
US7374930B2 (en) * 2002-05-21 2008-05-20 Expression Genetics, Inc. GLP-1 gene delivery for the treatment of type 2 diabetes
US7977098B2 (en) 2002-05-31 2011-07-12 Children's Hospital Medical Center Antigenic binding patterns of norovirus to human histo-blood group antigens
DE60336063D1 (de) * 2002-05-31 2011-03-31 Childrens Hosp Medical Center Verfahren, zusammensetzung und kit für die antigenbindung von norwalk-ähnlichen viren
US20040016013A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent
US20040014704A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent induces tolerance
US20040014698A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
CA2503437A1 (en) * 2002-10-24 2004-05-06 Biogen Idec Ma Inc. High expression locus vector based on ferritin heavy chain gene locus
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US20080026077A1 (en) * 2002-11-12 2008-01-31 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
WO2005032574A1 (en) * 2003-10-03 2005-04-14 The Board Of Trustees Of The Leland Stanford Junior University Modulation of gastrointestinal epithelium proliferation through the wnt signaling pathway
US20050208032A1 (en) * 2004-01-16 2005-09-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
CA2634080A1 (en) * 2005-12-20 2007-06-28 Arana Therapeutics Limited Anti-inflammatory dab
AU2007285472B2 (en) * 2006-03-30 2013-10-24 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo
JP2011504366A (ja) * 2007-11-26 2011-02-10 プラント バイオサイエンス リミティド エンドリシン活性を有する新規ポリペプチド及びその使用
EP2296683B1 (en) 2008-06-03 2017-01-25 University Of Rochester AvrA PROTEIN FOR TREATING INFLAMMATORY INTESTINAL DISEASE AND MANAGING SYMPTOMS THEREOF
US20100068233A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Modifiable dosage form
US20100068152A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable particle or polymeric based final dosage form
US20100069821A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable medicament release-sites final dosage form
US20100068235A1 (en) * 2008-09-16 2010-03-18 Searete LLC, a limited liability corporation of Deleware Individualizable dosage form
US20100068153A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo activatable final dosage form
US20100068256A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable medicament release-substance
US20100068275A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Personalizable dosage form
US20100068254A1 (en) * 2008-09-16 2010-03-18 Mahalaxmi Gita Bangera Modifying a medicament availability state of a final dosage form
US20100069887A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Multiple chamber ex vivo adjustable-release final dosage form
GB0908949D0 (en) 2009-05-26 2009-07-01 Plant Bioscience Ltd Novel polypeptides having endolysin activity and uses thereof
EP2440582B1 (en) 2009-06-09 2018-11-07 Children's Hospital Medical Center Antigen-norovirus p-domain monomers and dimers, antigen-norovirus p-particle molecules, and methods for their making and use
US9321803B2 (en) 2013-07-12 2016-04-26 Children's Hospital Medical Center Compositions and methods for inhibiting norovirus infection
ES2865825T3 (es) 2014-04-01 2021-10-18 Rubius Therapeutics Inc Procedimientos y composiciones para inmunomodulación
US20160160229A1 (en) * 2014-12-09 2016-06-09 THC Farmaceuticals, Inc. Methods of producing antibody-rich cannabis and honeysuckle plants
EP3600397A4 (en) 2017-03-28 2021-01-27 Children's Hospital Medical Center NOROVIRUS PARTICLE VACCINES AND THEIR MANUFACTURING AND USE PROCEDURES
US20230023615A1 (en) * 2019-12-13 2023-01-26 Dnalite Therapeutics, Inc. Compositions and methods for biological delivery vehicles
US20230051811A1 (en) * 2019-12-20 2023-02-16 Translate Bio, Inc Rectal delivery of messenger rna

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643579A (en) * 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
US5997859A (en) * 1988-03-21 1999-12-07 Chiron Corporation Method for treating a metastatic carcinoma using a conditionally lethal gene
WO1990005787A1 (en) 1988-11-23 1990-05-31 The Regents Of The University Of California Position-specific insertion vectors and method of using same
ES2116269T3 (es) 1989-03-21 1998-07-16 Vical Inc Expresion de secuencias exogenas de polinucleotidos en un vertebrado.
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
ATE157012T1 (de) 1989-11-03 1997-09-15 Univ Vanderbilt Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
AU3972893A (en) * 1992-04-03 1993-11-08 Baylor College Of Medicine Gene therapy using the intestine
WO1994016057A1 (en) * 1992-12-31 1994-07-21 Dana-Farber Cancer Institute, Inc. Enhancer sequence for modulating expression in epithelial cells
SG54115A1 (en) * 1993-04-27 1998-11-16 Gerber Scient Products Inc Thermal printing apparatus with improved power supply
CA2162497A1 (en) 1993-06-10 1994-12-22 Sheila Connelly Adenoviral vectors for treatment of hemophilia
US5681744A (en) * 1995-03-17 1997-10-28 Greenstein; Robert J. Delivery and expression of heterologus genes using upstream enhancer regions of mammalian gene promoters
US5885971A (en) * 1995-03-24 1999-03-23 The Regents Of The University Of California Gene therapy by secretory gland expression
JPH11507340A (ja) 1995-06-07 1999-06-29 アルザ コーポレイション 遺伝子構築物の経口送出
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US6248720B1 (en) * 1996-07-03 2001-06-19 Brown University Research Foundation Method for gene therapy using nucleic acid loaded polymeric microparticles
US6225290B1 (en) * 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation

Also Published As

Publication number Publication date
US20050026863A1 (en) 2005-02-03
CA2264744A1 (en) 1998-03-26
EP0939590A1 (en) 1999-09-08
EP0939590B1 (en) 2006-03-15
ATE320186T1 (de) 2006-04-15
US6258789B1 (en) 2001-07-10
WO1998011779A1 (en) 1998-03-26
DE69735496T2 (de) 2006-09-21
US6831070B2 (en) 2004-12-14
EP0939590A4 (en) 2002-09-04
ES2256896T3 (es) 2006-07-16
AU4422197A (en) 1998-04-14
US6225290B1 (en) 2001-05-01
US20020039574A1 (en) 2002-04-04
AU729457B2 (en) 2001-02-01
DE69735496D1 (de) 2006-05-11
JP2001502303A (ja) 2001-02-20

Similar Documents

Publication Publication Date Title
DK0939590T3 (da) Nukleinsyre til anvendelse i genterapi, der involverer ekspression af tarmcellegener
Martin et al. Gene transfer to intact mesenteric arteries by electroporation
US6747014B2 (en) Compositions and methods for non-parenteral delivery of oligonucleotides
Yin et al. Gene therapy for streptozotocin-induced diabetic mice by electroporational transfer of naked human insulin precursor DNA into skeletal muscle in vivo
WO2001030965A3 (en) Methods of in vivo gene transfer using a sleeping beauty transposon system
DE69914932D1 (de) Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis
HUP9801207A2 (hu) Nukleinsavat tartalmazó készítmények, előállításuk és alkalmazásuk
JPH11502413A (ja) 分泌腺発現による遺伝子治療
ATE327326T1 (de) Fhit proteine und nukleinsäuren sowie darauf basierende verfahren
Islamov et al. Epidural stimulation combined with triple gene therapy for spinal cord injury treatment
EA005496B1 (ru) Растворимый гетеродимерный рецептор цитокина
US20120270920A1 (en) Compositions and methods for treatment of pouchitis
ATE371031T1 (de) Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs
CN119405623B (zh) 一种用于肺纤维化治疗的靶向纳米递送系统及其制备方法
BR9812138A (pt) Métodos e composições para terapias empregando genes codificando proteìnas segregadas tal como interferon-beta
Jeschke et al. Effect of multiple gene transfers of insulinlike growth factor I complementary DNA gene constructs in rats after thermal injury
Baum et al. The mouth is a gateway to the body: gene therapy in 21st century dental practice
Culliton Designing Cells to Deliver Drugs: As technical roadblocks slow some approaches to gene therapy, new avenues may lead to treatments for disorders including AIDS, cancer, heart disease, and emphysema
Schjerling The basics of gene doping
Jin et al. Nose‐to‐Brain Delivery of Chlorella vulgaris Extracellular Vesicles for Antidepressant Effects
CN104232685A (zh) 一种可活体成像监测肝脏中NF-κB活性的小鼠模型及其构建方法
RU2137498C1 (ru) Способ лечения дисбактериозов кишечника
Morikawa et al. Impaired G‐CSF production at post‐transcriptional level in a patient with chronic idiopathic neutropenia
CN119775354A (zh) 一种激活Treg细胞发挥抗炎作用的多肽
Baum A Critical Reason for Conducting Clinical Trials Is that Results with Humans Are Not Necessarily Predictable from Preclinical Studies